Favipiravir (nama lain Movfor)

AntiViral

Bahan Aktif: Molnupiravir

Dalam Stok: Hanya 22 pek kiri

Molnupiravir, rawatan antivirus oral untuk COVID-19

Penyakit: Disease 2019

Favipiravir (nama lain Movfor) nama lain: Bexovid Covid Emorivir Favipiravir Lagevrio Molenzavir Molvir Monuvir Paxlovid Ritonavir

Favipiravir (nama lain Movfor) 200mg

Pakej	Setiap Pil	Harga Istimewa
200 caps Penghantaran Ekspres Percuma	$5.49	~~$1466~~ -26% Hanya $1097
160 caps Penghantaran Ekspres Percuma	$5.60	~~$1173~~ -24% Hanya $896
120 caps Penghantaran Ekspres Percuma	$5.79	~~$880~~ -21% Hanya $695
80 caps Penghantaran Ekspres Percuma	$6.18	~~$587~~ -16% Hanya $494
40 caps Penghantaran Biasa Percuma	$7.33	$293

Product Description

Common use
Easily distributed oral antivirals are urgently needed to treat coronavirus disease-2019 (COVID-19), prevent progression to severe illness, and block transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report the results of a Phase 2a trial evaluating the safety, tolerability, and antiviral efficacy of molnupiravir in the treatment of COVID-19.

Dosage and direction

Eligible participants included outpatients with confirmed SARS-CoV-2 infection and symptom onset within 7 days. Participants were randomized 1:1 to 200 mg molnupiravir or placebo, or 3:1 to molnupiravir (400 or 800 mg) or placebo, twice-daily for 5 days.
Antiviral activity was assessed as time to undetectable levels of viral RNA by reverse transcriptase polymerase chain reaction and time to elimination of infectious virus isolation from nasopharyngeal swabs.

Results

Among 202 treated participants, virus isolation was significantly lower in participants receiving 800 mg molnupiravir (1.9%) versus placebo (16.7%) at Day 3 (p = 0.02). At Day 5, virus was not isolated from any participants receiving 400 or 800 mg molnupiravir, versus 11.1% of those receiving placebo (p = 0.03). Time to viral RNA clearance was decreased and a greater proportion overall achieved clearance in participants administered 800 mg molnupiravir versus placebo (p = 0.01). Molnupiravir was generally well tolerated, with similar numbers of adverse events across all groups.

Conclusions

Molnupiravir is the first oral, direct-acting antiviral shown to be highly effective at reducing nasopharyngeal SARS-CoV-2 infectious virus and viral RNA and has a favorable safety and tolerability profile.